Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ADT Inc (ADT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ADT Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.42 (market cap $5.07B), while ADT Inc trades at $7.35 (market cap $5.44B). The key difference: ACADIA Pharmaceuticals Inc. and ADT Inc are close in size by market cap, and ADT Inc pays a 2.95% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ADT | |
|---|---|---|
Market Cap | $5.07B | $5.44B |
Sector | Health | Industrials |
52-Week High | $29.41 | $8.85 |
52-Week Low | $20.06 | $6.30 |
Enterprise Value | $4.19B | $13.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
ADT trades at $7.51, down 1.7% today, amid strong technical momentum with bullish moving averages and ADX signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.23 beating estimates of $0.22, and improving profitability with net margin reaching 11.86% in 2025. Recent news highlights ADT's Zacks upgrade to Buy and strong Q2 results with 18% operating cash flow growth.
ADT presents a compelling value opportunity with attractive valuation multiples (P/E 10.35, EV/EBITDA 4.93) and bullish analyst sentiment (47% Buy ratings). Key risks include high debt levels ($7.51B long-term debt) and competitive pressures in security services. The stock's technical strength and fundamental improvements support a positive near-term outlook, though investors should monitor debt management and industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →
